Onkos Surgical and Vivex Biomedical, Inc. have come together to provide a portfolio of tissue products to support the needs of musculoskeletal oncologists and their patients. This commitment strengthens Onkos Surgical’s ability to enhance outcomes, decrease complications and improve recovery following musculoskeletal tumor and limb salvage surgery.
Nutrition 21, LLC, a leading developer and marketer of efficacious, patented nutritional products whose health benefits are substantiated with clinical research, announced today that Sara O’Brien has joined as General Counsel of JDS Therapeutics, and its wholly owned subsidiary Nutrition 21.
Nutrition 21, LLC (“Nutrition 21”) is proud to announce the presentation of new clinical study results supporting the bioavailability of Nitrosigine® bonded arginine silicate (ASI), titled, “A Pharmacokinetic Evaluation of the Duration of Effect of Inositol-Stabilized Arginine Silicate and Arginine Hydrochloride in Healthy Adult Males.” The study was presented on April 3rd, 2016 to scientists …
Onkos Surgical, a dedicated surgical oncology company founded to bring innovation, advocacy and passion to the surgical oncology marketplace, supported a difficult chondrosarcoma case with the use of a 3D printed medical model.
JDS Therapeutics, LLC, a privately held specialty pharmaceutical company and its Nutrition 21 LLC nutritional ingredient subsidiary, announced today that it has closed a $16 million Series B institutional equity financing round led by 1315 Capital, a Philadelphia-based investment firm specializing in healthcare.
Onkos Surgical, an innovative surgical oncology startup founded by Patrick Treacy, Antony Koblish and 1315 Capital, has announced it has closed a Series A round of financing led by 1315 Capital to bring innovation, advocacy and passion to the surgical oncology marketplace.
Encore Dermatology, Inc. announced today that it has begun to commercialize Hylatopic®, Tetrix™, and BenzEFoam™, three highly regarded and established U.S. topical dermatology products acquired from Valeant Pharmaceuticals. In addition to the founders, principal investors will be Essex Woodlands, 1315 Capital and Longitude Capital.
Adele Oliva shares how she chooses companies to invest in with Arianne Cohen from Bloomberg: “I look for great teams, because they can create outstanding returns as well as save your bacon in tough situations, particularly in the growth stage, where I focus. In health care, we live and die by management’s experience and ability …
Medium.com identifies Adele Oliva as part of the new wave of female investors starting their own funds as she launches 1315 Capital.
Forbes identifies Adele Oliva as one of the few women in venture capital. According to data from the National Venture Capital Association, the number of female venture capitalists is actually declining.